Skip to Content
Chair and DEO, Obstetrics and GynecologyProfessor of Obstetrics and Gynecology
- Maternal/Fetal Medicine
Primary Office: 31140-A PFPIowa City, IA 52242
BS, Psychology, Baylor University, Waco, TexasBS, Biology and Biochemistry, Texas Christian University, Fort Worth, TexasMD, Medicine, Southwestern Medical School, University of Texas, Dallas, Texas
Residency, Obstetrics and Gynecology, Parkland Memorial Hospital, Dallas, TexasResidency, Obstetrics and Gynecology, Georgetown University Affilated Hospitals, Washington, D.C.Fellowship, Maternal-Fetal Medicine, Georgetown University, Washington, D.C.
Interdisciplinary Graduate Program in Molecular and Cellular BiologyInterdisciplinary Graduate Program in Translational BiomedicineMedical Scientist Training Program
Dr. Leslie has received consistent research funding since 1989 and is the recipient of more than 22 peer-reviewed grants. Among these are the Reproductive Scientist Development Program (RSDP) and the American Obstetrical and Gynecologic Foundation/Burroughs Wellcome Fellowship. These mentored grants, received while undertaking post-doctoral research training in the laboratories of Drs. Janice Chou, intramural NICHD, and Kathryn Horwitz, the University of Colorado, were followed by the award of an R03, R21, and R29 from NIH. Her latest work is supported by the NCI via an R01 entitled, “Targeted Therapy for Endometrial Cancer” in addition to numerous foundation and Cancer Center awards. Leslie has served on numerous NIH study sections and editorial boards of peer-reviewed journals.
Dr. Leslie now trains post-doctoral fellows, residents, and students in her own laboratory that investigates the molecular biology of hormone action and hormone receptors in reproductive tissues. Her greatest research contribution has focused on the response to steroid stimulation and the phenotypic and genomic mechanisms in endometrial cancer. New areas of focus include sub-cellular localization of progesterone receptors, proteomics as a tool for cancer screening, and progesterone receptor cross-talk with the growth factors and other signaling molecules. Dr. Leslie’s laboratory has also made observations pertaining to the molecular pathways affected in preeclampsia, and these findings were the subject of plenary talks at the Society for Maternal-Fetal Medicine meetings in 2008 and 2009. Dr. Leslie continues to be active in the clinical care of women with pregnancy complications and serves as an examiner for the American Board of Obstetrics and Gynecology.
Epigenetic Modification Restores Functional PR Expression in Endometrial Cancer Cells.
Curr Pharm Des.
2013 July 19. Meng X,
Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53..
2013 March. 128(3):461-9.
Drug Resistance Mediated by AEG-1/MTDH/LYRIC..
Adv Cancer Res.
The Onco-placental Gene Placenta-specific protein 1 (PLAC1) is Highly Expressed in Endometrial Tumors and Cell Line.
Obstet Gynecol Intl.
2013. Devor E,
DE Mik J,
Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma..
Experimental and therapeutic medicine.
2012 April. 3(4):677-682.
Endometrial cancer: potential treatment and prevention with progestin-containing intrauterine devices..
Obstetrics and gynecology.
2012 February. 119(2 Pt 2):419-20.
Hormones and receptors in endometrial cancer.
Proc Obstet Gynecol.
2011 July 28. 2(1):Article 1 -25 p.
Date Last Modified: 04/12/2016 -
Copyright © 2015 The University of Iowa. All Rights Reserved.